ArticleFuture oncology (London, England)2024

Evaluation of CDK4/6 inhibitors in first-line in symptomatic and asymptomatic patients with metastatic breast cancer.

İrem Öner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.